Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations
Authors
Keywords
-
Journal
International Journal of General Medicine
Volume Volume 13, Issue -, Pages 1395-1409
Publisher
Informa UK Limited
Online
2020-12-07
DOI
10.2147/ijgm.s285191
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
- (2020) David Z. I. Cherney et al. DIABETOLOGIA
- GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
- (2020) Daiji Kawanami et al. Frontiers in Pharmacology
- Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
- (2020) Davide Margonato et al. HEART FAILURE REVIEWS
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- GLP-1 Receptor Agonists and Kidney Protection
- (2019) Eulalia Valentina Greco et al. Medicina-Lithuania
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
- (2019) David M. Williams et al. Diabetes Therapy
- The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- (2018) Keizo Kanasaki CLINICAL SCIENCE
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
- (2018) Russell Scott et al. DIABETES OBESITY & METABOLISM
- Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
- (2018) Giuseppe Coppolino et al. PHARMACOLOGICAL RESEARCH
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study
- (2017) Samira Bell et al. BMC Nephrology
- Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease
- (2017) Wei-Hao Hsu et al. Oncotarget
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- (2017) Sophia Zoungas et al. Lancet Diabetes & Endocrinology
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
- (2016) Paola Fioretto et al. DIABETOLOGIA
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study
- (2016) Yu-Hsin Chen et al. PLoS One
- Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
- (2016) Judith van Dalem et al. BMJ-British Medical Journal
- Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
- (2016) Judith van Dalem et al. BMJ-British Medical Journal
- Urine Albumin/Creatinine Ratio Below 30 mg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality
- (2016) Ki‐Chul Sung et al. Journal of the American Heart Association
- Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
- (2016) Young-Gun Kim et al. Journal of Diabetes Research
- A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Dia
- (2015) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Metformin initiation and renal impairment: a cohort study in Denmark and the UK
- (2015) Christian Fynbo Christiansen et al. BMJ Open
- Hypoglycemia in Patients with Diabetes and Renal Disease
- (2015) Mazen Alsahli et al. Journal of Clinical Medicine
- Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
- (2014) Hala Yamout et al. AMERICAN JOURNAL OF NEPHROLOGY
- Cardiovascular Actions of Incretin-Based Therapies
- (2014) John R. Ussher et al. CIRCULATION RESEARCH
- Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
- (2013) Maximilian von Eynatten et al. Cardiovascular Diabetology
- Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
- (2013) Ian H. de Boer et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
- (2012) Nils Ekström et al. BMJ Open
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
- (2009) M. F. Moen et al. Clinical Journal of the American Society of Nephrology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search